ALT Altimmune, Inc.
ALT Altimmune, Inc.
Healthcare · Biotechnology
Market read
POC $2.96 · VWAP $3.76 · -20.2% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
ALT Price Structure
Loading timeframes…
Peers
Every watchlist ALT belongs to, members best 30-day change first — ALT highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
Reported EPS $-0.12 versus analyst consensus of $-0.12 (+4.0%).
full note →Against street estimates
How ALT's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about ALT from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 40 days ago · Jul 9
- Altimmune Q1 2026 Earnings: Narrower Loss Drives Positive ...
- Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
- Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
- Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
- Altimmune Announces Proposed Underwritten Public Offering of Securities
ALT research tape
3 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.